| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nina Vanessa Kraguljac, David Matthew White, Jennifer Ann Hadley, Kristina Visscher, David Knight, Lawrence ver Hoef, Blessing Falola, Adrienne Carol Laht. Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone. NeuroImage. Clinical. vol 10. 2016-10-06. PMID:26793436. |
to describe abnormalities in large scale functional networks in unmedicated patients with schizophrenia and to examine effects of risperidone on networks. |
2016-10-06 |
2023-08-13 |
Not clear |
| Hsaing-Yuan Yu, Chih Yin Hsiao, Kao Chin Chen, Lan-Ting Lee, Wei Hung Chang, Mei Hung Chi, I Hui Lee, Po See Chen, Yen Kuang Yan. A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study. Schizophrenia research. vol 169. issue 1-3. 2016-09-28. PMID:26395153. |
a comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--a nationwide study. |
2016-09-28 |
2023-08-13 |
Not clear |
| Roy R Reeve. A Case Study of Gamma Waves in a Woman with Recent Psychotic Symptoms. The Neurodiagnostic journal. vol 56. issue 2. 2016-09-13. PMID:27373056. |
she was diagnosed with schizophrenia and treated with risperidone, ultimately at a dose of 3 mg daily, with improvement. |
2016-09-13 |
2023-08-13 |
Not clear |
| Sinaya Vaisburd, Zeev Shemer, Adva Yeheskel, Eliezer Giladi, Illana Goze. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Scientific reports. vol 5. 2016-09-07. PMID:26553741. |
risperidone and nap protect cognition and normalize gene expression in a schizophrenia mouse model. |
2016-09-07 |
2023-08-13 |
mouse |
| Sinaya Vaisburd, Zeev Shemer, Adva Yeheskel, Eliezer Giladi, Illana Goze. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Scientific reports. vol 5. 2016-09-07. PMID:26553741. |
thus, the combination of nap and standard of care risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia. |
2016-09-07 |
2023-08-13 |
mouse |
| Sefa Vayısoğlu, Elif Anıl Yağcıoğl. [Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 25. issue 3. 2016-09-06. PMID:25219694. |
the number of controlled studies evaluating augmentation of clozapine in schizophrenia patients are highest for risperidone and lamotrigine add on treatments. |
2016-09-06 |
2023-08-13 |
Not clear |
| Juan J Fernández-Miranda, Victoria Caramés-García, Arantxa Sánchez-Garcí. Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up. Journal of clinical psychopharmacology. vol 35. issue 6. 2016-08-30. PMID:26421461. |
effectiveness, good tolerability, and high compliance of doses of risperidone long-acting injectable higher than 75 mg in people with severe schizophrenia: a 3-year follow-up. |
2016-08-30 |
2023-08-13 |
human |
| Juan J Fernández-Miranda, Victoria Caramés-García, Arantxa Sánchez-Garcí. Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up. Journal of clinical psychopharmacology. vol 35. issue 6. 2016-08-30. PMID:26421461. |
the aim of this study was to evaluate effectiveness, tolerability, and adherence to treatment with high doses of risperidone long-acting injectable (rlai) in patients with severe schizophrenia.it is a 3-year prospective, observational study of patients with severe (clinical global impression severity scale [cgi-s] score of ≥5) schizophrenia according to international classification of diseases (icd-10) criteria. |
2016-08-30 |
2023-08-13 |
human |
| Serena Deiana, Akihito Watanabe, Yuki Yamasaki, Naoki Amada, Tetsuro Kikuchi, Colin Stott, Gernot Riede. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behavioural pharmacology. vol 26. issue 8 Spec No. 2016-08-22. PMID:26287433. |
collectively, the combined activity of aripiprazole on dopamine d2 and serotonin 5ht1a receptors appears to provide a significant advantage over risperidone and olanzapine with respect to the rescue of cognitive deficits reminiscent of schizophrenia. |
2016-08-22 |
2023-08-13 |
human |
| Nobuhisa Kanahara, Hiroshi Kimura, Masaomi Iy. Reply to "concern over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia". Schizophrenia research. vol 173. issue 1-2. 2016-08-22. PMID:26971073. |
reply to "concern over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia". |
2016-08-22 |
2023-08-13 |
Not clear |
| Mirjam Moerbeek, Weng-Kee Won. Optimal treatment allocation for placebo-treatment comparisons in trials with discrete-time survival endpoints. Statistics in medicine. vol 34. issue 27. 2016-08-18. PMID:26119759. |
as an application, we revisit a risperidone maintenance treatment trial in schizophrenia and use our proposed methodology to redesign it and compare merits of our optimal design. |
2016-08-18 |
2023-08-13 |
human |
| Elisabeth Giraud-Baro, Daniel Dassa, Florent De Vathaire, Ricardo P Garay, Joelle Obei. Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study). BMC psychiatry. vol 16. 2016-08-15. PMID:26772753. |
previous studies showed functional improvement in stable patients with schizophrenia treated with risperidone long-acting injection (lai). |
2016-08-15 |
2023-08-13 |
Not clear |
| Jan Volavka, Pál Czobor, Leslie Citrome, Richard A Van Dor. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS spectrums. vol 19. issue 5. 2016-07-21. PMID:24284234. |
this study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia. |
2016-07-21 |
2023-08-12 |
Not clear |
| Stephanie Sampson, Prakash Hosalli, Vivek A Furtado, John M Davi. Risperidone (depot) for schizophrenia. The Cochrane database of systematic reviews. vol 4. 2016-07-21. PMID:27078222. |
risperidone (depot) for schizophrenia. |
2016-07-21 |
2023-08-13 |
Not clear |
| Delbert G Robinson, Juan A Gallego, Majnu John, Georgios Petrides, Youssef Hassoun, Jian-Ping Zhang, Leonardo Lopez, Raphael J Braga, Serge M Sevy, Jean Addington, Charles H Kellner, Mauricio Tohen, Melissa Naraine, Natasha Bennett, Jessica Greenberg, Todd Lencz, Christoph U Correll, John M Kane, Anil K Malhotr. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia bulletin. vol 41. issue 6. 2016-07-20. PMID:26338693. |
a randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. |
2016-07-20 |
2023-08-13 |
human |
| G Piriu, E Torac, L E Gaman, L Iosif, I C Tivig, C Delia, M Gilca, I Stoian, V Atanasi. Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia. Journal of medicine and life. vol 8. issue 4. 2016-07-18. PMID:26664488. |
clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia. |
2016-07-18 |
2023-08-13 |
human |
| G Piriu, E Torac, L E Gaman, L Iosif, I C Tivig, C Delia, M Gilca, I Stoian, V Atanasi. Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia. Journal of medicine and life. vol 8. issue 4. 2016-07-18. PMID:26664488. |
we have investigated the effects of clozapine and risperidone on estradiol levels in men with schizophrenia. |
2016-07-18 |
2023-08-13 |
human |
| G Piriu, E Torac, L E Gaman, L Iosif, I C Tivig, C Delia, M Gilca, I Stoian, V Atanasi. Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia. Journal of medicine and life. vol 8. issue 4. 2016-07-18. PMID:26664488. |
our study found decreased estradiol levels in men with schizophrenia treated with clozapine and risperidone, while prolactin levels were increased only in the risperidone treated group. |
2016-07-18 |
2023-08-13 |
human |
| b' Francesco Bartoli, Cristina Crocamo, Massimo Clerici, Giuseppe Carr\\xc3\\xa. Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 10. 2016-07-12. PMID:26164075.' |
eight studies were included with data suitable for carrying out four different comparisons: clozapine vs. olanzapine (including n=877 individuals with schizophrenia); clozapine vs. risperidone (n=660); olanzapine vs. risperidone (n=738); quetiapine vs. risperidone (n=186). |
2016-07-12 |
2023-08-13 |
human |
| Abdallah Ahnaou, Ria Biermans, Wilhelmus H Drinkenbur. Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats. PloS one. vol 11. issue 1. 2016-07-12. PMID:26808689. |
the present study used the auditory paired click paradigm in passive awake sprague dawley rats to 1) model disruption of aep waveforms and oscillations as observed in schizophrenia by peripheral administration of amphetamine and the n-methyl-d-aspartate (nmda) antagonist phencyclidine (pcp); 2) confirm the potential of the antipsychotics risperidone and olanzapine to attenuate these disruptions; 3) evaluate the potential of mglur2 agonist ly404039 and pde10 inhibitor pq-10 to improve aep deficits in both the amphetamine and pcp models. |
2016-07-12 |
2023-08-13 |
rat |